Literature DB >> 12142377

Host genetic polymorphism analysis in cervical cancer.

Eric S Calhoun1, Renee M McGovern, Carol A Janney, James R Cerhan, Stephen J Iturria, David I Smith, Bobbie S Gostout, David H Persing.   

Abstract

BACKGROUND: The natural history of cervical cancer comprises a latency period that probably involves long-term immunologic tolerance of human papillomavirus infection. Identifying host determinants of viral persistence may help to better understand the mechanisms of tolerance and may lead to the development of tests that can allow more focused follow-up of high-risk individuals.
METHODS: Genotypic frequencies of 12 polymorphic loci in four candidate genes from 127 cervical cancer patients were compared with a control group of 108 female blood donors. Genotypes were determined by PCR amplification and direct sequencing of isolated genomic DNA.
RESULTS: The tumor necrosis factor-alpha (TNFalpha) -238 polymorphism was significantly underrepresented in cervical cancer patients [heterozygotes (HETs), odds ratio (OR) = 0.33; 95% confidence interval (CI), 0.11-0.96], as was the TNFalpha -376 polymorphism (P = 0.02; 0% for any variant genotype in cases vs 4.7% in controls). The NRAMP1 3' untranslated region STP+86 polymorphism also appeared to be inversely associated with cervical cancer, but this result did not reach statistical significance (HET, OR = 0.57; 95% CI, 0.32-1.02). The p53 codon 72 arginine allele showed a suggestive negative association with cervical cancer (HET, OR = 0.49; 95% CI, 0.14-1.63; homozygotes, OR = 0.35; 95% CI, 0.11-1.17). The remaining alleles tested showed no association with cervical cancer.
CONCLUSIONS: We identified host genetic polymorphisms that may be associated with cervical cancer risk, some of which have been linked to potential functional effects on cellular immune responses or antigen processing. We failed to confirm earlier reports of increased cervical cancer susceptibility in women who harbor the p53 P72R allele. Although our findings support the general hypothesis that host immunogenetic determinants other than class II MHC may be important in the development of cervical cancer, further analysis of the HLA gene cluster comprising the implicated TNFalpha single-nucleotide polymorphisms will be required to determine whether their association is linkage independent.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142377

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  20 in total

1.  TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk.

Authors:  Gisela Barbisan; Luis Orlando Pérez; Anahí Contreras; Carlos Daniel Golijow
Journal:  Tumour Biol       Date:  2012-05-17

2.  CD95 rs1800682 polymorphism and cervical cancer risk: evidence from a meta-analysis.

Authors:  Yan Zhang; Shengchun Tong; Lihua Guan; Fei Na; Wei Zhao; Li Wei
Journal:  Tumour Biol       Date:  2013-10-11

3.  Tumor Necrosis Factor Alpha (-238 / -308) and TNFRII-VNTR (-322) Polymorphisms as Genetic Biomarkers of Susceptibility to Develop Cervical Cancer Among Tunisians.

Authors:  Sabrina Zidi; Mouna Stayoussef; Ferjeni Zouidi; Samir Benali; Ezzedine Gazouani; Amel Mezlini; Besma Yacoubi-Loueslati
Journal:  Pathol Oncol Res       Date:  2014-08-12       Impact factor: 3.201

4.  Characterization of Single-Nucleotide Polymorphisms in the Tumor Necrosis Factor α Promoter Region and in Lymphotoxin α in Squamous Intraepithelial Lesions, Precursors of Cervical Cancer.

Authors:  Miriam Enriqueta Nieves-Ramirez; Oswaldo Partida-Rodriguez; Pedro Eduardo Alegre-Crespo; Maria Del Carmen Tapia-Lugo; Martha Esthela Perez-Rodriguez
Journal:  Transl Oncol       Date:  2011-12-01       Impact factor: 4.243

5.  A systemic assessment of the association between tumor necrosis factor alpha 308 G/A polymorphism and risk of cervical cancer.

Authors:  Hua-Lian Zhang; Yi-Jie Zhang
Journal:  Tumour Biol       Date:  2013-03-15

6.  New approach reveals CD28 and IFNG gene interaction in the susceptibility to cervical cancer.

Authors:  Valeska B Guzman; Anatoly Yambartsev; Amador Goncalves-Primo; Ismael D C G Silva; Carmen R N Carvalho; Julisa C L Ribalta; Luiz Ricardo Goulart; Natalia Shulzhenko; Maria Gerbase-Delima; Andrey Morgun
Journal:  Hum Mol Genet       Date:  2008-03-12       Impact factor: 6.150

7.  Association between TNF-α polymorphisms and cervical cancer risk: a meta-analysis.

Authors:  Li Liu; Xi Yang; Xiaojun Chen; Tinjing Kan; Yan Shen; Zengyan Chen; Zhibin Hu
Journal:  Mol Biol Rep       Date:  2011-06-14       Impact factor: 2.316

8.  Differences between blood donors and a population sample: implications for case-control studies.

Authors:  Jean Golding; Kate Northstone; Laura L Miller; George Davey Smith; Marcus Pembrey
Journal:  Int J Epidemiol       Date:  2013-07-03       Impact factor: 7.196

9.  TNF-alpha rs1800629 polymorphism is not associated with HPV infection or cervical cancer in the Chinese population.

Authors:  Ning Wang; Duo Yin; Shulan Zhang; Heng Wei; Shizhuo Wang; Yang Zhang; Yanming Lu; Shuyan Dai; Wei Li; Qiao Zhang; Yao Zhang
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

10.  Genetic susceptibility of cervical cancer.

Authors:  Xiaojun Chen; Jie Jiang; Hongbing Shen; Zhibin Hu
Journal:  J Biomed Res       Date:  2011-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.